MHS-1031

Microbiome Health Sciences · Phase 2 active Small molecule

At a glance

Generic name	MHS-1031
Also known as	Panosyl-isomaltooligosaccharide
Sponsor	Microbiome Health Sciences
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD (PHASE2)
Tolerability Study of Panosyl Isomaltooligosaccharides (PIMO), in Subjects With Chronic Idiopathic Constipation (CIC) (NA)
Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MHS-1031 CI brief — competitive landscape report
MHS-1031 updates RSS · CI watch RSS
Microbiome Health Sciences portfolio CI